The HLCS Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human A-549 lung adenocarcinoma cell line, engineered to disrupt the HLCS gene encoding holocarboxylase synthetase. This loss-of-function model enables investigation of HLCS-dependent biotinylation processes essential for metabolic regulation and chromatin modification. As a polyclonal knockout pool, the cells retain heterogeneous editing events across the population, providing a robust tool for studying gene function without clonal selection biases.
The host A-549 cell line originates from a 58-year-old Caucasian male with lung carcinoma and is widely utilized as a model of type II alveolar epithelial cells. A-549 cells exhibit features of lung adenocarcinoma and are extensively applied in cancer biology, toxicology, and respiratory research. Their well-characterized growth properties and genetic background make them an ideal platform for metabolic and epigenetic studies in a cancer-relevant context.
HLCS catalyzes the ATP-dependent covalent attachment of biotin to apocarboxylases, including acetyl-CoA carboxylase (ACACA), pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCCA/PCCB), and methylcrotonyl-CoA carboxylase (MCCC1/MCCC2), activating these enzymes for fatty acid synthesis, gluconeogenesis, and amino acid catabolism. Additionally, HLCS mediates histone biotinylation, particularly on histones H3 and H4, influencing chromatin architecture and gene expression. HLCS activity is modulated by biotin availability and regulatory inputs from SIRT1 deacetylase, AMPK, mTORC1, MYC, and SP1 transcription factor. Disruption of HLCS uncouples these metabolic and epigenetic networks, providing a model to dissect biotin-dependent signaling.
In A-549 cells, HLCS knockout abrogates biotinylation of key carboxylases, directly impairing propionate metabolism, leucine degradation, and gluconeogenic flux while perturbing fatty acid biosynthesis. The concurrent loss of histone biotinylation alters chromatin marks, including H3K9biotin, potentially reprogramming gene expression profiles linked to cellular proliferation and metabolic adaptation in cancer. This cell model is thus particularly relevant for exploring the intersection between metabolism and epigenetic regulation in lung adenocarcinoma, where altered nutrient sensing and oncogenic signaling converge on HLCS-dependent processes.
Researchers can employ these polyclonal knockout cells in diverse assays, such as streptavidin pulldown and western blotting to assess global biotinylation status, RT-qPCR for transcriptomic changes, and carboxylase activity assays to quantify metabolic enzyme function. The model facilitates metabolic flux analysis to trace biotin-dependent pathways, immunofluorescence for nuclear histone biotinylation, and ChIP-qPCR targeting H3K9biotin for chromatin studies. Applications include drug screening for HLCS inhibitors, investigation of biotin metabolism in cancer, modeling of multiple carboxylase deficiency, and exploration of SIRT1/AMPK/mTORC1 regulatory axes. For further information, please contact Ascent Research.
